Last reviewed: 18/10/22 by Nina Fuller Shavel

Non-pharmacological interventions

symposium presentations

View resources
Last reviewed: 18/10/22 by Rizwana Patel | Aamira Manjra | Andrew Walker

Ongoing SACT drug interactions – a retrospective, single centre audit of practice

Abstracts

View resources
Last reviewed: 18/10/22 by May Low | Asswade Boodhoo | Celine Moco | Sebastian Masento | Anish Tailor | Danielle Ohana

Patient Experience of the Pilot Bortezomib Self-Administration Service at University College London NHS Foundation Trust (UCLH).

Abstracts

View resources
Last reviewed: 18/10/22 by Mariam Azizi MRPharmS, PGCert | Dr Vikash Dodhia, MRPharmS, BPharms, MSc, PhD | Hei Wan Wendy Ng MBA, MPharmS,. PGDip, IPres | Dr Neel Bhuva, MSc MRCP FRCR | Dr Ridwan Ahmed, MBBS, MPhil, FMCR

Pharmacogenomic testing for dihydropyrimidine dehydrogenase (DPD) polymorphisms in patients receiving fluoropyrimidine therapies at Mount Vernon Cancer Centre

Abstracts

View resources
Last reviewed: 18/10/22 by Imran Ahmad | Prakash S. S. | Rajnish Vasant Nagarkar | Krishna Chaitanya Puligundla | Lokesh K. N. | Rakesh Reddy Boya | Ankit Baldevbhai Patel | Lovenish Goyal | Aniket Thoke | Jigar Gordhanbhai Patel | Ajay Omprakash Mehta | Ghanshyam Nanubhai Patel | Ronak Patel | Mujtaba A. Khan

Randomized, multicentre, open-label, two-period crossover study to demonstrate Bioequivalence between pegylated liposomal doxorubicin (PLD) and Caelyx® pegylated liposomal doxorubicin in patients with advanced ovarian cancer

Abstracts

View resources